Company: PSTV
Filing Date: 2025-04-01
Form Type: CORRESP
Source: 0001193125-25-070569
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: CORRESP
Chunk 0
---
| Hogan Lovells US LLP Harbor East       
 100 International Drive Suite 2000     
 Baltimore, MD 21202 T +1 410 659 2700  
 F +1 410 659 2701 www.hoganlovells.com |

April 1, 2025 BY EDGAR Messrs. Daniel Crawford and Jason Drory Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549

| Re: | Plus Therapeutics, Inc. |

Preliminary Proxy Statement on Schedule 14A Filed March 14, 2025 File No. 001-34375 Dear Messrs. Crawford and Drory: On behalf of Plus Therapeutics, Inc. (the “Company”), this letter responds to comments made by the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) regarding the Company’s above-referenced preliminary proxy statement in the Staff’s letter dated March 24, 2025. The Company has also filed an amended preliminary proxy statement on the date hereof (the “Amended Preliminary Proxy Statement”). Set forth below are the Staff’s numbered comments in italic type, followed by the response to each comment submitted on behalf of the Company. Preliminary Proxy Statement on Schedule 14A General 1. We note your references in your preliminary proxy statement to an “alternative cashless exercise” feature in the Series B Warrants. The term “cashless exercise” is generally understood to allow a warrant holder to exercise a warrant without paying cash for the exercise price and reducing the number of shares receivable by the holder by an amount equal in value to the aggregate exercise price the holder would otherwise pay to exercise the warrant(s). In cashless exercises, it is expected that the warrant holder receives fewer shares than they would if they opted to pay the exercise price in cash. Please clarify your disclosure throughout by revising the references to “alternative cashless exercise” and exclusively using the term “zero exercise price” or another appropriate term that conveys that, in addition to the company receiving no cash upon the “alternative cashless exercise,” the warrant holders would be entitled to receive more shares than they would under the cash exercise terms or the cashless exercise terms of the warrants.

Messrs. Daniel Crawford and Jason Drory Division of Corporation Finance April 1, 2025 Page 2 In response to the Staff’s comment, the Company revised the disclosure in the Amended Preliminary Proxy Statement